Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic neonatal mesenchymal stromal cells
- Development stage
- Phase 1
- Lead developer
- Emory University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intravitreal, Intrathecal, Intramyocardial, Intracoronary, Local Injection
01
Overview
Allogeneic neonatal mesenchymal stromal cells (nMSCs) are a cell therapy product derived from neonatal tissues, such as the umbilical cord or placenta. These cells are characterized by their high proliferative capacity, low immunogenicity, and potent immunomodulatory and regenerative properties. In clinical applications, particularly for dilated cardiomyopathy (DCM), nMSCs are administered intravenously to improve cardiac function and left ventricular ejection fraction. Their mechanism of action involves the secretion of various paracrine factors, including cytokines and growth factors, which help reduce inflammation, prevent fibrosis, and stimulate endogenous tissue repair mechanisms. The therapy is currently being investigated in Phase 1 clinical trials sponsored by Emory University.
- Other names
- neonatal mesenchymal stromal cellsneonatal mesenchymal cellsallogeneic neonatal mesenchymal cells
Beyond the preview
Go deeper on allogeneic neonatal mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic neonatal mesenchymal stromal cells.